Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. is recognized as a leading developer of induced pluripotent stem cell (iPSC)-derived cancer therapeutics, particularly focusing on NK cell therapies that address challenges such as off-the-shelf availability and reduced manufacturing costs. Early clinical data presented at the recent American College of Rheumatology meeting highlighted the promising efficacy of its off-the-shelf CD19 CAR-T product candidate, FT819, in treating patients with systemic lupus erythematosus, showcasing significant improvements in key health scores without severe adverse effects. The company's strong pipeline and innovative technology position it favorably in the competitive landscape of cellular immunotherapies, contributing to a positive outlook on its stock performance.

Bears say

Fate Therapeutics Inc. faces significant risks that could negatively impact its stock, including the potential failure of its product FT819 to demonstrate meaningful clinical efficacy compared to existing CAR-T therapies and concerns regarding safety and immunogenicity. Furthermore, the company may encounter challenges related to partnerships and unfavorable reactions from regulatory agencies, which could hinder its development efforts. Additionally, medium-term dilution risk poses a financial threat, potentially affecting shareholder value and investor confidence.

Fate Therapeutics (FATE) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 6 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.